Coherus And Formycon’s Ranibizumab Rapidly Ramps Up In US

Cimerli Biosimilar To Lucentis Captures 38% Of Total Market Volume In December 2023

 
• By David Wallace
  
Graphs and data reflected in eye
Formycon and Coherus see positive data for ranibizumab • Source: Shutterstock

More from Biosimilars

More from Products